Dawa ya UKIMWI yagunduliwa?

[Tasia I]

Monday, 12 July 2010

[FONT=Tahoma,Calibri,Verdana,Geneva,sans-serif]
B[/FONT]endera ya Marekani nchi ambayo wanasayansi wake wanadaiwa kuwa wamegundua dawa ya Ukimwi

Leon Bahati

WANASAYANSI nchini Marekani wamegundua chembechembe za kinga ambazo zinauwezo mkubwa wa kupambana na kuua virusi vya ugonjwa wa Ukimwi ambao hadi sasa hauna chanjo wala tiba ya uhakika.

Ugunduzi huo tayari umethibitishwa na wataalamu mbalimbali, ikiwemo Mamlaka ya Chakula na Dawa ya Marekani.

Vyombo mbalimbali vya habari vya kimataifa vimeripoti kuhusu ugunduzi huo ambao unaelekea kutoa mapambazuko mapya kwa ugonjwa huo hatari ambao umekuwa ukiathiri nguvu kazi sehemu mbalimbali duniani, hususan nchi zinazoendelea.

Wanasayansi hao wa Taasisi ya Magonjwa ya Kuambukiza na Mzio (Niaida) walieleza katika taarifa yao ya wiki iliyopita kuwa kwenye utafiti huo wamebaini aina mbili za chembechembe zinazoweza kumsaidia binadamu kupambana na virusi vya ukimwi.

Mkurugenzi wa Niaida, Dk Anthony Fauci alizitaja chembechembe hizo za kinga kuwa ni VRCO1 na VRCO2 ambazo utafiti wake umeonyesha kuwa zinaweza kuua virusi vya ukimwi kwa asilimia 90.

Kwa mujibu wa Shirika la Afya Duniani (WHO) dawa huthibitishwa pale uwezo wake wa kupambana na ugonjwa unapozidi asilimia 60.

Dk Fauci alisema hayo ni mafanikio makubwa ya kisayansi tangu wataalamu mbalimbali duniani waanze kufanya utafiti wa namna ya kutibu ugonjwa huo.

Alisema chembechembe hizo za kinga hizo VRCO1 na VRCO2 zinaweza kutumika katika kubaini aina mpya ya chanjo ambayo itamuwezesha binadamu kuwa na kinga dhidi ya virusi vya Ukimwi.

Kwa namna chembechembe hizo zinavyofanya kazi, alisema, zikitumika kama chanjo, mwili wa anayechanjwa unajenga kinga ambayo inavishambulia virusi vya Ukimwi na kuviua.

“Kwa sasa soko lina dawa za kupunguza nguvu na kasi ya virusi vya Ukimwi kuathiri chembechembe nyeupe za kujikinga na maradhi na hakuna tiba,” alisema Dk Fauci.

“Lakini utafiti huu ni njia mpya ya kuelekea kupata ufumbuzi wa kudumu katika utaalamu wa tiba.”

Hata hivyo, alisema utafiti huo unaweka matumaini zaidi katika kutoa chanjo ingawa baadaye utawezesha kusaidia kupatikana kwa tiba kamili.

Jinsi walivyoendesha utafiti huo, Dk Faci alisema walichukua sampuli mbalimbali za damu zenye virusi vya ukimwi kutoka maeneo mbalimbali duniani.

Katika sampuli hizo, alisema waliweza kupata aina karibu 200 za virusi vya ukimwi na walipozipambanisha na chembechembe za kinga za VRCO1 na VRCO2, virusi vilikufa bila kuathiri chembechembe nyingine za damu.

Hali hiyo aliilezea kuwa inathibitisha kuwa VRCO1 na VRCO2 zina uwezo wa kupambana na aina zote za virusi vya ukimwi.

Haya jamani habari njema ndo hizo, ila kwa me navoijua Africa hi sasa itaweka kiburi cha kuafanya ngono zembe kwa kiasi kikubwa hata hata kama chembechembe hizi zitakua na uwezo wa kuua kweli virusi vya ukimwi.

Matokeo yake yatakua kuri kwa kasi kwa yale magonjwa ya zinaa ya zamani kama kswende na gonorea na mengine, mimba kibao zisizotarajiwa, na matokeo yake watotot zaidi wa mtaani, vibaka, mateja n.k

 

[Mkandara]

Hizi habari za dawa kupatikana zinatangazwa Bongo tu au?.......

 

[FirstLady1]

Ngoja tusubiri tuone ...Kakini Dawa kubwa ya ukimwi ni kuacha ngono zembe

 

[Mkandara]

Ngoja tusubiri tuone ...Kakini Dawa kubwa ya ukimwi ni kuacha ngono zembe

Kwa sura nayoiona hapo juu itakuwa kazi kubwa kuacha ngono zembe hasa ukizingatia hiyo signature yako maanake tuisha katazwa hiana....Haaa haaa haaa!

 

[Bourgeoisie]

Kugunduliwa kwa tiba hii hakuji kutangua amri ya "MSIZINI".

 

[ELNIN0]

Hizi habari za dawa kupatikana zinatangazwa Bongo tu au?.......

Health News about "VRCO1" (CalorieLab Lab Notes)

 

[Ndibalema]

Sijui kwa nini hii habari imeletwa kwenye jukwaa la Siasa!
Anyway,
Kwa mujibu wa habari hiyo, sidhani kama ni dawa kama dawa hasa ila nafikiri ni kama ARV ambayo inapunguza tu makali ya virusi vya ukimwi na si kutibu.
Itakuwa ni good news kama itapatikana dawa ambayo itatibu kabisa.

 

[Rayase]

soma mwenyewe uone!

NIH-Led Scientists Find Antibodies that Prevent Most HIV Strains from Infecting Human Cells

 

[jossey1979]

Sijui kwa nini hii habari imeletwa kwenye jukwaa la Siasa!
Anyway,
Kwa mujibu wa habari hiyo, sidhani kama ni dawa kama dawa hasa ila nafikiri ni kama ARV ambayo inapunguza tu makali ya virusi vya ukimwi na si kutibu.
Itakuwa ni good news kama itapatikana dawa ambayo itatibu kabisa.

Hii habari nimeisikia asubuhi. Lakini presentation ya hii habari bado haieleweki vizuri kama ni kinga, Chanjo au inatibu kabisa.

But kama ni kweli hawa jamaa watakuwa ma-billionaires

 

[mujusi]

Kinga kubwa ya Ukimwi ndio kuacha ngono dawa ya ukimwi hakkuna hadi sasa samahani kwa kuiweka sawa sentense yako.

Ngoja tusubiri tuone ...Kakini Dawa kubwa ya ukimwi ni kuacha ngono zembe

 

[SMU]

Hivi ni 'dawa' ya UKIMWI au 'kinga' dhidi ya VVU?

 

[Mlalahoi]

Hii habari inachanganya,na kwa mtizamo wangu kinachochangia mkanganyiko huo ni matumizi ya neno DAWA. Angalia habari excerpt hii

Although none of the four patients were cured from the HIV infection, “this study represents an important milestone, suggesting that these results may one day translate into a sustainable therapeutic solution,” feels Dr Priya Shah and Dr David Schaffer from the University of California Berkeley.

SOURCE

Na wakati Waziri Mwakyusa amefuata mkumbo wa kupongeza upatikanaji wa "dawa" hiyo,huko Marekani the latest news ni kama HII ambapo suala la "ugunduzi wa tiba" haligusiwi kabisa.

Wakati kila mmoja wetu anatamani tiba ya ukimwi ipatikane hata leo ikiwezekana ni muhimu taarifa hizi za kitaalam zikafafanuliwa kitaalam pia.Habari kamili ni hii hapa chini

U.S. researchers have devised a gene therapy to produce HIV virus resistant cells that help in treating patients suffering from the deadly virus.



Initiated by Dr John Rossi and his contemporaries from City of Hope in Duarte, California, the study is a result of a two years’ pilot study in which stem cells were modified into anti-HIV proteins engineered cells with the help of cells of four HIV patients.

Though the study, which has a small sample size, was not designed to treat HIV in patients, it provides ground for more research on the therapeutic benefits of gene therapy for treating HIV in the future.

The report has been well timed as currently scientists are showing great interest in finding the potential behind the gene-based therapies to cure HIV completely.

The present research is based on a report named ‘Claims of HIV Cure by BMT Greeted With Caution’ that claimed that a bone marrow transplant of an American man in Germany cured his HIV too.

Study details
The study from City of Hope is the foremost experiment that examines gene therapy for treating HIV with the help of many factors taken together. It is similar to curing HIV using drug therapy that uses a combination of three drugs to kill the virus.

One factor used is a molecule that smashes through the CCR5 protein. The scientists also integrated this with an RNA molecule that hampers the HIV transcription beside a distraction RNA molecule that fights with the HIV protein for its receptor.

Dr Rossi says, “The combination provides very, very potent inhibition against all forms of HIV strains.”

All these factors were engineered genetically with the help of lentivirus, with the hematopoietic progenitor cells taken from the four subjects suffering from a non-Hodgkin's lymphoma.

According to the scientists, advantage of the lentiviral vector is that it infrequently mixes into the DNA of the cells in the promoter regions of genes.

All four patients were grafted with the new cells by day 11 of the study.

“Aside from cytopenias, serious transplant-related adverse events during the first 30 days after transplant included grade three hypotension in two patients, grade three hypoxia in two patients, grade three fever in one patient, and a central line infection in one patient,” reported the scientists.

Breakthrough study
Although none of the four patients were cured from the HIV infection, “this study represents an important milestone, suggesting that these results may one day translate into a sustainable therapeutic solution,” feels Dr Priya Shah and Dr David Schaffer from the University of California Berkeley.

The study titled ‘RNA-based gene therapy for HIV with lentiviral vector-modified CD34+ cells in patients undergoing transplantation for AIDS-related lymphoma’ has been detailed in the journal, Science Translational Medicine.

SOURCE

 

[ELNIN0]

Ngoja tusubiri tuone ...Kakini Dawa kubwa ya ukimwi ni kuacha ngono zembe

FL1, Yango na yango ndiyo jadi yetu waafrika, kinga unayoongelea wewe ni nadharia ya kwenye vitabu na mdomoni tu lakini kiukweli kama na hii si dawa basi space za kuzikia tutakosa.

 

[SMU]

Weneyewe waliofanya utafiti wametoa taarifa hii hapa(NIH-Led Scientists Find Antibodies that Prevent Most HIV Strains from Infecting Human Cells):

NIH-Led Scientists Find Antibodies that Prevent Most HIV Strains from Infecting Human Cells

Discovery to Advance HIV Vaccine Design, Antibody Therapy for Other Diseases

Scientists have discovered two potent human antibodies that can stop more than 90 percent of known global HIV strains from infecting human cells in the laboratory, and have demonstrated how one of these disease-fighting proteins accomplishes this feat.

According to the scientists, these antibodies could be used to design improved HIV vaccines, or could be further developed to prevent or treat HIV infection. Moreover, the method used to find these antibodies could be applied to isolate therapeutic antibodies for other infectious diseases as well.

This image shows the atomic structure of the antibody VRC01 (blue and green) binding to HIV (grey and red). The precise site of VRC01-HIV binding (red) is a subset of the area of viral attachment to the primary immune cells HIV infects.

“The discovery of these exceptionally broadly neutralizing antibodies to HIV and the structural analysis that explains how they work are exciting advances that will accelerate our efforts to find a preventive HIV vaccine for global use,” says Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health. “In addition, the technique the teams used to find the new antibodies represents a novel strategy that could be applied to vaccine design for many other infectious diseases.”

Led by a team from the NIAID Vaccine Research Center (VRC), the scientists found two naturally occurring, powerful antibodies called VRC01 and VRC02 in an HIV infected individual's blood using a novel molecular device they developed that hones in on the specific cells that make antibodies against HIV. The device is an HIV protein that the scientists modified so it would react only with antibodies specific to the site where the virus binds to cells it infects.

The scientists found that VRC01 and VRC02 neutralize more HIV strains with greater overall strength than previously known antibodies to the virus.

The researchers also determined the atomic-level structure of VRC01 when it is attaching to HIV. This has enabled the team to define how the antibody works and to precisely locate where it attaches to the virus. With this knowledge, they have begun to design components of a candidate vaccine that could teach the human immune system to make antibodies similar to VRC01 that might prevent infection by the vast majority of HIV strains worldwide.

NIAID scientists Peter D. Kwong, Ph.D., John R. Mascola, M.D., and Gary J. Nabel, M.D., Ph.D., led the two research teams. A pair of articles about these findings appears today in the online edition of Science.

“We have used our knowledge of the structure of a virus—in this case, the outer surface of HIV—to refine molecular tools that pinpoint the vulnerable spot on the virus and guide us to antibodies that attach to this spot, blocking the virus from infecting cells,” explains Dr. Nabel, the VRC director.

Finding individual antibodies that can neutralize HIV strains anywhere in the world has been difficult because the virus continuously changes its surface proteins to evade recognition by the immune system. As a consequence of these changes, an enormous number of HIV variants exist worldwide. Even so, scientists have identified a few areas on HIV’s surface that remain nearly constant across all variants. One such area, located on the surface spikes used by HIV to attach to immune system cells and infect them, is called the CD4 binding site. VRC01 and VRC02 block HIV infection by attaching to the CD4 binding site, preventing the virus from latching onto immune cells.

“The antibodies attach to a virtually unchanging part of the virus, and this explains why they can neutralize such an extraordinary range of HIV strains,” says Dr. Mascola, the deputy director of the VRC.

With these antibodies in hand, a team led by Dr. Kwong, chief of the structural biology section at the VRC, determined the atomic-level molecular structure of VRC01 when attached to the CD4 binding site. They then examined this structure in light of natural antibody development to ascertain the steps that would be needed to elicit a VRC01-like antibody through vaccination.

Antibody development begins with the mixing of genes into new combinations within the immune cells that make antibodies. Examination of the structure of VRC01 attached to HIV suggested that, from a genetic standpoint, the immune system likely could produce VRC01 precursors readily. The researchers also confirmed that VRC01 does not bind to human cells—a characteristic that might otherwise lead to its elimination during immune development, a natural mechanism the body employs to prevent autoimmune disease.

In the final stage of antibody development, antibody-producing B cells recognize specific parts of a pathogen and then mutate, or mature, so the antibody can bind to the pathogen more firmly. VRC01 precursors do not bind tightly to HIV, but rather mature extensively into more powerfully neutralizing forms. This extensive antibody maturation presents a challenge for vaccine design. In their paper, Dr. Kwong and colleagues explore how this challenge might be addressed by designing vaccine components that could guide the immune system through this stepwise maturation process and facilitate the generation of a VRC01-like antibody from its precursors. The scientists currently are performing research to identify these components.

“The discoveries we have made may overcome the limitations that have long stymied antibody-based HIV vaccine design,” says Dr. Kwong.

The two research teams included NIAID scientists from the VRC, the Laboratory of Immunoregulation, and the Division of Clinical Research, all in Bethesda, Md.; as well as researchers from Beth Israel Deaconess Medical Center in Boston; Columbia University in New York; Harvard Medical School and Harvard School of Public Health in Boston; The Rockefeller University in New York City; and University of Washington in Seattle.

###​

References:
Wu X et al. Rational design of envelope surface identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science. DOI: 10.1126/science.1187659 (2010).

Zhou T et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science. DOI: 10.1126/science.1192819 (2010).

 

[ngoshwe]

Ngoja tusubiri tuone ...Kakini Dawa kubwa ya ukimwi ni kuacha ngono zembe

yote tisa.. kumi ni kuzingatia mahubiri ya mtumishi mpakwa mafuta NABII NA MTUME TITO,,

 

[PhD]

uuhhhh afadhali kula vitu kwa kwenda mbele sasa.

 

[Mwanamayu]

Mimi sijaipenda dawa au kinga hii kwani ugonjwa huu kwa asilimia 99 ni wakujitakia! Sasa sample zilikuwa 200 je, hii sample ni representative? Je, kama kuna aina ya 201, itakinga au kutibu? Mungu hajaribiwi!

 

[Lambardi]

Dalili nzuri na yenye mafanikio poleni sana wataalaam mnaokesha....ngoja ifanyiwe majaribio ya kutosha kwa mabara yotendio waipitishe

 

[Kanyafu Nkanwa]

AIDS Breakthrough!!III


Jul 8, 2010 6:12pm by James Grimes

This is great news!! Hopefully this will be able to help a lot of people before the AIDS epidemic kills more people.


Amplify’d from www.foxnews.com

U.S. researchers discovered two powerful antibodies that neutralize more than 90 percent of all known strains of the HIV virus in the lab, new research released Thursday showed.
​

NIH-led scientists discovered the antibodies known as VRCO1 and VRCO2 that prevent most HIV strains from infecting human cells. The find is a potential breakthrough for advancing HIV [SIZE=+0]vaccine[/SIZE] design, and antibody therapy for other diseases.
​

The authors, whose work was due to be published in the July 9 issue of Science, were also able to demonstrate how one of these disease-fighting proteins [SIZE=+0]gets the job[/SIZE] done.
​

“The discovery of these exceptionally broadly neutralizing antibodies to HIV and the structural analysis that explains how they work are exciting advances that will accelerate our efforts to find a preventive HIV vaccine for global use,” said Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health.
​

“In addition, the technique the teams used to find the new antibodies represents a novel strategy that could be applied to vaccine design for many other infectious diseases,” Fauci stressed in a statement.
​

The team of virologists found that the two antibodies were produced naturally and found in the blood of HIV-positive people.
​

They were able to isolate these antibodies using a new molecular device they developed. It zeroes in on specific cells that make antibodies against HIV. The device is an HIV protein scientists modified to react only with antibodies specific to the site where the virus binds to cells it infects.
​

Leading two research teams were NIAID scientists Peter Kwong, Ph.D., John Mascola, MD, and Gary Nabel, MD, Ph.D.
​

“We have used our knowledge of the structure of a virus — in this case, the outer surface of HIV — to refine molecular [SIZE=+0]tools[/SIZE] that pinpoint the vulnerable spot on the virus and guide us to antibodies that attach to this spot, blocking the virus from infecting cells,” explained Nabel.
​

Mascola added that: “the antibodies attach to a virtually unchanging part of the virus, and this explains why they can neutralize such an extraordinary range of HIV strains.”
​

Click here to read more from NewsCore.
​

 

[Ndahani]

Bwana wewe AIDS is still a threat..imagine mtu maskini anayeugua AIDS kule kwetu Kayenze, pembeni mwa ziwa victoria,ambaye hata dawa za malaria tu bado ni issue, atawezaje kupata faida ya reaserch hizi zilizoko lab za Marekani? Hapa we talk something of months or years before we get the benefit.